What Is HRT?

Educational only. Not medical advice. HRT is a medical treatment with real benefits and real risks. The decision to start, continue, or stop HRT should be made with a licensed clinician who knows your full health history. If you experience chest pain, sudden severe headache, leg swelling, or signs of stroke, call 911 immediately.

Millions of women suffer through menopause without treatment that could help them. Not because HRT does not work. It is the most effective treatment available for hot flashes and night sweats. Not because it is too dangerous. For appropriate candidates, the benefits outweigh the risks. But because a single study in 2002, reported in headlines that dramatically overstated the danger and ignored the nuance, created a generation of fear that persists more than two decades later.

That fear is not supported by current evidence. NAMS, ACOG, and the Endocrine Society all support HRT for symptomatic women under 60 or within 10 years of menopause onset. The picture is more nuanced than “hormones cause cancer.” Understanding that nuance is the first step toward an informed decision.

Hormone replacement therapy (HRT), also called menopausal hormone therapy (MHT) in clinical guidelines, replaces the estrogen and progesterone that decline during perimenopause and menopause. It is FDA-approved for both symptom relief and osteoporosis prevention. The delivery route (oral, patch, gel, vaginal) affects both convenience and risk profile. This is not a one-size-fits-all treatment.

• HRT replaces estrogen (and progesterone, if you have a uterus) that declines during menopause. It is the most effective treatment for hot flashes and night sweats
• The Women’s Health Initiative (2002) caused widespread fear of HRT, but subsequent reanalysis showed the risks were concentrated in older women who started HRT well past menopause
• The “timing hypothesis” is now central to clinical guidance: HRT initiated within 10 years of menopause onset or before age 60 has a more favorable risk-benefit profile than HRT started later
• Estrogen-only therapy (for women without a uterus) has a different and generally more favorable risk profile than combined estrogen-progestogen therapy
• “Bioidentical” is a marketing term, not a regulatory category. Estradiol and micronized progesterone are bioidentical AND available as FDA-approved products
• HRT is not one product. It spans oral tablets, transdermal patches, topical gels, vaginal rings, and more, each with different risk and convenience profiles

HRT is most commonly prescribed for women experiencing moderate to severe vasomotor symptoms (hot flashes, night sweats) that affect quality of life. It is also indicated for prevention of postmenopausal osteoporosis and for genitourinary syndrome of menopause (vaginal dryness, painful intercourse, urinary symptoms).

The best candidates for systemic HRT are women under 60 years old or within 10 years of menopause onset, with moderate to severe symptoms, no absolute contraindications (see the Side Effects and Risks guide), and who have had a thorough risk assessment.

Women who have had premature menopause (before age 40) or early menopause (before age 45), whether natural or surgical, have a particularly strong case for HRT. Without hormone replacement, these women face accelerated bone loss, increased cardiovascular risk, and other consequences of prolonged estrogen deficiency that exceed the risks of treatment for most individuals.

This distinction matters for both safety and treatment planning.

If you have had a hysterectomy (no uterus), you take estrogen only. No progestogen is needed because there is no endometrium to protect. The WHI estrogen-only arm showed a more favorable risk profile, including no increased breast cancer risk and possible reduction.

If you have a uterus, you need estrogen plus a progestogen. Estrogen alone stimulates the uterine lining, which without progestogen opposition increases the risk of endometrial hyperplasia and endometrial cancer. The progestogen protects the endometrium. This combined therapy is what the WHI estrogen-plus-progestin arm studied.

The type of progestogen matters. Micronized progesterone (Prometrium) has a different risk profile than synthetic progestins like medroxyprogesterone acetate (Provera/MPA). The WHI used MPA. More recent evidence suggests micronized progesterone may carry lower breast cancer risk, though long-term data is more limited. This is an important conversation to have with your clinician.

“Bioidentical” means the hormone molecule is structurally identical to what your body naturally produces. Estradiol is bioidentical estrogen. Micronized progesterone is bioidentical progesterone. Both are available as FDA-approved products (Estrace, Climara, Prometrium, and many generics).

The marketing confusion arises because some compounding pharmacies and clinics use “bioidentical” to imply their compounded products are safer or more natural than FDA-approved options. NAMS, ACOG, and the FDA have all cautioned against this claim. Compounded products are not FDA-approved, are not tested for safety and efficacy, and have variable quality control. They are not inherently safer than FDA-approved bioidentical products.

Compounded hormones are not inherently "more natural" than Climara or Prometrium. Both contain the same bioidentical molecules. The difference is that FDA-approved products have clinical trial data, standardized quality controls, and regulatory oversight that compounded products do not. You can get bioidentical hormones with FDA approval.

Prescribing decisions depend on symptom severity and type, menopausal stage (perimenopause vs postmenopause), uterine status (hysterectomy or intact uterus), cardiovascular and thrombotic risk factors, breast cancer risk assessment, personal preferences regarding delivery route, and cost and insurance coverage.

The delivery route (oral, transdermal patch, gel, vaginal) affects both convenience and risk profile. Transdermal estrogen bypasses the liver and carries lower VTE (blood clot) risk than oral estrogen, which is clinically significant for women with VTE risk factors. See the forms of HRT guide for detailed comparison.

• What specific HRT products do you prescribe? FDA-approved, compounded, or both?
• How do you assess my individual risk profile before prescribing?
• Do you follow NAMS or Endocrine Society guidelines for prescribing decisions?
• What is the total monthly cost including medication, consultations, labs, and any platform fees?
• How are dose adjustments handled?
• If you prescribe compounded products, why are you choosing compounded over FDA-approved alternatives?